CureVac NV banner

Wall St Price Targets

CVAC Price Targets Summary
CureVac NV

There are no price targets for CVAC.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
CureVac NV Competitors:
Price Targets
NYXH
Nyxoah SA
258% Upside
APA
APA Corp (US)
10% Upside
8961
Mori Trust Sogo Reit Inc
7% Upside
MRVL
Marvell Technology Group Ltd
-34% Downside

Revenue
Forecast

98% / Year
Past Growth
-22% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
98% / Year
Past Growth
-22% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

Over the last 5 years, the compound annual growth rate for Revenue has been 98%. The projected CAGR for the next 4 years is -22%.

Operating Income
Forecast

N/A
Past Growth
-27% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss
N/A
Past Growth
-27% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss

The compound annual growth rate for Operating Income over the next 4 years is -27%.

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is CVAC's stock price target?
Not Available

CVAC does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for CureVac NV?
Projected CAGR
-22%

Over the last 5 years, the compound annual growth rate for Revenue has been 98%. The projected CAGR for the next 4 years is -22%.

What is the Operating Income forecast for CureVac NV?
Projected CAGR
-27%

The compound annual growth rate for Operating Income over the next 4 years is -27%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett